Usefulness of olanzapine as an adjunct to opioid treatment and for the treatment of neuropathic pain

Anesthesiology

Volumn 116, Issue 1, 2012, Pages 159-169

  Torigoe, Kazuhiro ^a   Nakahara, Kae ^a   Rahmadi, Mahardian ^a   Yoshizawa, Kazumi ^a   Horiuchi, Hiroshi ^b   Hirayama, Shigeto ^c   Imai, Satoshi ^a   Kuzumaki, Naoko ^a   Itoh, Toshimasa ^a   Yamashita, Akira ^b   Shakunaga, Kiyoshi ^e   Yamasaki, Mitsuaki ^e   Nagase, Hiroshi ^c   Matoba, Motohiro ^d   Suzuki, Tsutomu ^a   Narita, Minoru ^b  

^a Department of Toxicology ^*  (Japan)

^b HOSHI UNIVERSITY   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

^e UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 3 INDOLECARBOXYLIC ACID [1 [2 (METHYLSULFONYLAMINO)ETHYL] 4 PIPERIDINYLMETHYL] ESTER; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; DOPAMINE; GRANISETRON; HALOPERIDOL; MEPYRAMINE; MORPHINE; MUSCARINIC M1 RECEPTOR; OLANZAPINE; OPIATE; PENTOBARBITAL; PROCHLORPERAZINE; RACLOPRIDE; RISPERIDONE; RITANSERIN; TELENZEPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CATALEPSY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINE RELEASE; DOSE RESPONSE; DRUG EFFECT; ELECTROENCEPHALOGRAM; ELECTROMYOGRAM; FERRET; HYPERALGESIA; IN VIVO STUDY; MALE; MICRODIALYSIS; MOUSE; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RETCHING; SLEEP DISORDER; VOMITING;

ANALGESICS, OPIOID; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BRAIN CHEMISTRY; CATALEPSY; CLOZAPINE; DOPAMINE; DRUG THERAPY, COMBINATION; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; GASTROINTESTINAL TRANSIT; HYPERALGESIA; MALE; MICE; MICE, INBRED C57BL; MICRODIALYSIS; MORPHINE; NEURALGIA; PAIN MANAGEMENT; RECEPTORS, SEROTONIN; SCIATICA; SLEEP DISORDERS; VOMITING;

EID: 84655166489     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e31823c7e56     Document Type: Article

References (34)

1. WHO: Cancer Pain Relief, 2nd edition. Geneva, World Health Organisation, 1996
2. Aparasu R, McCoy RA, Weber C, Mair D, Parasuraman TV: Opioid-induced emesis among hospitalized nonsurgical patients: Effect on pain and quality of life. J Pain Symptom Manage 1999; 18:280-8 (Pubitemid 29469706)
3. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli- Goudas M, Chew PW, Lau J, Carr D, American Pain Society: Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review. J Pain 2003; 4:231-56 (Pubitemid 36807905)
4. Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F: Review article: Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 2004; 19: 379-90 (Pubitemid 38297106)
5. Hornby PJ: Central neurocircuitry associated with emesis. Am J Med 2001; 111:106S-12S (Pubitemid 34032001)
6. Porreca F, Ossipov MH: Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: Mechanisms, implications, and management options. Pain Med 2009; 10:654-62
7. Herndon CM, Jackson KC 2nd, Hallin PA: Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy 2002; 22:240-50 (Pubitemid 34112884)
8. Iasnetsov VV, Drozd IuV, Shashkov VS: Emetic and antiemetic properties of regulatory peptides. Biull Eksp Biol Med 1987; 103:586-8
9. Rousseau P: Nonpain symptom management in terminal care. Clin Geriatr Med 1996; 12:313-27 (Pubitemid 26152326)
10. Licup N: Olanzapine for nausea and vomiting. Am J Hosp Palliat Care 2010; 27:432-4
11. Pilowsky I, Crettenden I, Townley M: Sleep disturbance in pain clinic patients. Pain 1985; 23:27-33 (Pubitemid 15236649)
12. Morin CM, Gibson D, Wade J: Self-reported sleep and mood disturbance in chronic pain patients. Clin J Pain 1998; 14: 311-4 (Pubitemid 28560153)
13. O'Brien EM, Waxenberg LB, Atchison JW, Gremillion HA, Staud RM, McCrae CS, Robinson ME: Negative mood mediates the effect of poor sleep on pain among chronic pain patients. Clin J Pain 2010; 26:310-9
14. Zgierska A, Brown RT, Zuelsdorff M, Brown D, Zhang Z, Fleming MF: Sleep and daytime sleepiness problems among patients with chronic noncancerous pain receiving longterm opioid therapy: A cross-sectional study. J Opioid Manag 2007; 3:317-27 (Pubitemid 351166543)
15. Becker PM: Treatment of sleep dysfunction and psychiatric disorders. Curr Treat Options Neurol 2006; 8:367-75 (Pubitemid 44349490)
16. Nakamura A, Narita M, Miyoshi K, Shindo K, Okutsu D, Suzuki M, Higashiyama K, Suzuki T: Changes in the rewarding effects induced by tramadol and its active metabolite M1 after sciatic nerve injury in mice. Psychopharmacology 2008; 200:307-16
17. Shiokawa M, Narita M, Nakamura A, Kurokawa K, Inoue T, Suzuki T: Usefulness of the dopamine system-stabilizer aripiprazole for reducing morphine-induced emesis. Eur J Pharmacol 2007; 570:108-10 (Pubitemid 47247679)
18. Suzuki T, Nurrochmad A, Ozaki M, Khotib J, Nakamura A, Imai S, Shibasaki M, Yajima Y, Narita M: Effect of a selective GABA(B) receptor agonist baclofen on the mu-opioid receptor agonist-induced antinociceptive, emetic and rewarding effects. Neuropharmacology 2005; 49:1121-31 (Pubitemid 41608636)
19. Morelli M, Di Chiara G: Catalepsy induced by SCH 23390 in rats. Eur J Pharmacol 1985; 117:179-85 (Pubitemid 16232488)
20. Cole JO, Clyde DJ: Extrapyramidal side effects and clinical response to the phenothiazines. Rev Can Biol 1961; 20: 565-74
21. Narita M, Takei D, Shiokawa M, Tsurukawa Y, Matsushima Y, Nakamura A, Takagi S, Asato M, Ikegami D, Narita M, Amano T, Niikura K, Hashimoto K, Kuzumaki N, Suzuki T: Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer. Eur J Pharmacol 2008; 600:105-9
22. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates, 4th edition. San Diego, Academic Press, 1998
23. Kamei J, Ohsawa M, Misawa M, Nagase H, Kasuya Y: Effect of diabetes on the morphine-induced inhibition of gastrointestinal transit. Nihon Shinkei Seishin Yakurigaku Zasshi 1995; 15:165-9
24. Narita M, Niikura K, Nanjo-Niikura K, Narita M, Furuya M, Yamashita A, Saeki M, Matsushima Y, Imai S, Shimizu T, Asato M, Kuzumaki N, Okutsu D, Miyoshi K, Suzuki M, Tsukiyama Y, Konno M, Yomiya K, Matoba M, Suzuki T: Sleep disturbances in a neuropathic pain-like condition in the mouse are associated with altered GABAergic transmission in the cingulate cortex. Pain 2011; 152:1358-72
25. Costello DJ, Borison HL: Naloxone antagonizes narcotic self blockade of emesis in the cat. J Pharmacol Exp Ther 1977; 203:222-30 (Pubitemid 8203904)
26. Rubin A, Winston J: The role of the vestibular apparatus in the production of nausea and vomiting following the administration of morphine to man; clinical and experimental data including the effects of dramamine and benzedrine. J Clin Invest 1950; 29:1261-6
27. Swegle JM, Logemann C: Management of common opioidinduced adverse effects. Am Fam Physician 2006; 74: 1347-54 (Pubitemid 44607306)
28. Horn CC: Is there a need to identify new anti-emetic drugs? Drug Discov Today Ther Strateg 2007; 4:183-7 (Pubitemid 351837431)
29. Obata Y, Otake Y, Takayama K: Feasibility of transdermal delivery of prochlorperazine. Biol Pharm Bull 2010; 33: 1454-7
30. Lohr L: Chemotherapy-induced nausea and vomiting. Cancer J 2008; 14:85-93
31. Passik SD, Lundberg J, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, Cooper M, Dugan W: A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 2002; 23:526-32 (Pubitemid 34627037)
32. Bakshi VP, Geyer MA: Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 1995; 122:198-201 (Pubitemid 26019155)
33. Coccurello R, Caprioli A, Ghirardi O, Conti R, Ciani B, Daniele S, Bartolomucci A, Moles A: Chronic administration of olanzapine induces metabolic and food intake alterations: A mouse model of the atypical antipsychotic- associated adverse effects. Psychopharmacology 2006; 186:561-71 (Pubitemid 43855843)
34. Monti JM: The structure of the dorsal raphe nucleus and its relevance to the regulation of sleep and wakefulness. Sleep Med Rev 2010; 14:307-17